ArticleOncology letters2024

Regorafenib plus programmed death‑1 inhibitors vs. regorafenib monotherapy in second‑line treatment for advanced hepatocellular carcinoma: A systematic review and meta‑analysis.

Zhao Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.